Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.

EXCLUSIVE: Verve Ventures, Verve’s film financing and sales division, has boarded Good Boy to represent worldwide rights, ...

Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose ...

AI, human and cultural understanding business Verve has named Peter Latham as director as part of 11 promotions at the ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited ...

EXCLUSIVE: Verve has welcomed agent Barrett Bischoff to its Talent team and promoted Lacey Hunsucker to Talent Agent. In his ...

Verve Therapeutics (VERV) delivered earnings and revenue surprises of 19.44% and 90.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Verve Therapeutics (VERV – Research Report), ...

Verve Therapeutics Inc. (VERV) on Thursday reported a loss of $50 million in its fourth quarter. The Boston-based company said it had a loss of 58 cents per share. The results beat Wall Street ...